Why the study?
Diabetic cardiomyopathy is a serious complication of T2DM with unfavorable prognosis, and while icariin showed potential therapeutic efficacy on T2DM, the underlying mechanism of how it improved DCM in rat models remained to be investigated.
Does Icariin improve diabetic cardiomyopathy and reduce extracellular matrix proteins in a rat model of type 2 diabetes?
Population
Streptozotocin and high-glucose-high-fat diet-induced T2DM rat models
Comparison
Icariin treatment vs control group
Design
Animal experimental study
Authors
Loading...
ICA may improve DCM in T2DM rat models; leaves open human translation and efficacy trials.
Does Icariin improve diabetic cardiomyopathy and reduce extracellular matrix proteins in a rat model of type 2 diabetes?
In a rat model of type 2 diabetes, Icariin ameliorated diabetic cardiomyopathy and reduced extracellular matrix proteins, suggesting potential therapeutic efficacy.
Qiao et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: